Wan Yi Ching Esther, Chan Kui Ming
Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.
Key Laboratory of Biochip Technology, Biotech and Health Centre, Shenzhen Research Institute of City University of Hong Kong, Shenzhen 518172, China.
Biomedicines. 2021 Jun 19;9(6):694. doi: 10.3390/biomedicines9060694.
Oncohistones have emerged as a new area in cancer epigenetics research. Recent efforts to catalogue histone mutations in cancer patients have revealed thousands of histone mutations across different types of cancer. In contrast to previously identified oncohistones (H3K27M, H3G34V/R, and H3K36M), where the mutations occur on the tail domain and affect histone post-translational modifications, the majority of the newly identified mutations are located within the histone fold domain and affect gene expression via distinct mechanisms. The recent characterization of the selected H2B has revealed previously unappreciated roles of oncohistones in nucleosome stability, chromatin accessibility, and chromatin remodeling. This review summarizes recent advances in the study of H2B oncohistones and other emerging oncohistones occurring on other types of histones, particularly those occurring on the histone fold domain.
癌组蛋白已成为癌症表观遗传学研究的一个新领域。近期对癌症患者组蛋白突变进行编目的努力揭示了不同类型癌症中数以千计的组蛋白突变。与先前鉴定出的癌组蛋白(H3K27M、H3G34V/R和H3K36M)不同,这些突变发生在尾部结构域并影响组蛋白的翻译后修饰,而新鉴定出的大多数突变位于组蛋白折叠结构域内,并通过不同机制影响基因表达。最近对选定的H2B的表征揭示了癌组蛋白在核小体稳定性、染色质可及性和染色质重塑方面以前未被认识到的作用。本综述总结了H2B癌组蛋白以及其他出现在其他类型组蛋白上的新兴癌组蛋白,特别是那些发生在组蛋白折叠结构域上的癌组蛋白的研究进展。